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Abstract
The Cytochrome P450 2B6 (CYP2B6) enzyme makes a small contribution to hepatic nicotine metabolism relative to CYP2A6,
but CYP2B6 is the primary enzyme responsible for metabolism of the smoking cessation drug bupropion. Using CYP2A6
genotype as a covariate, we find that a non-coding polymorphism in CYP2B6 previously associated with smoking cessation
(rs8109525) is also significantly associated with nicotine metabolism. The association is independent of the well-studied
non-synonymous variants rs3211371, rs3745274, and rs2279343 (CYP2B6*5 and *6). Expression studies demonstrate that
rs8109525 is also associated with differences in CYP2B6 mRNA expression in liver biopsy samples. Splicing assays
demonstrate that specific splice forms of CYP2B6 are associated with haplotypes defined by variants including rs3745274
and rs8109525. These results indicate differences in mRNA expression and splicing as potential molecular mechanisms by
which non-coding variation in CYP2B6 may affect enzymatic activity leading to differences in metabolism and smoking
cessation.
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Introduction
Tobacco use remains the largest cause of preventable mortality
worldwide and improvements in smoking cessation treatments
have great potential to impact both public health and individual
quality of life. Smoking-related phenotypes are highly heritable
[1–3]; genetic studies therefore provide a powerful tool to reveal
the biology underlying smoking behavior and dependence. Single
nucleotide polymorphisms (SNPs) near the CYP2A6 nicotine
metabolism gene were among the few loci associated with
consumption of cigarettes per day (CPD) with genome-wide
significance [4,5]. We have since determined that these SNPs are
proxies for several functionally important CYP2A6 haplotypes [6].
Such synthetic associations, resulting from the coincidental linkage
of common markers with multiple less-frequent causal variants,
have been proposed as sources of unexplained GWAS findings [7].
With this in mind, we embarked on a study of the nearby and
similarly complex CYP2B6 locus. CYP2B6 plays a small role in
nicotine metabolism [8,9] but is the primary enzyme responsible
for the metabolism of substrates including methadone, efavirenz,
cyclophosphamide, and bupropion [10], a drug prescribed for
smoking cessation. A candidate gene association study recently
reported a non-coding polymorphism in CYP2B6 (rs8109525)
associated with smoking cessation, both with and without
bupropion treatment [11]. Other studies have reported a potential
link between the CYP2A6 gene and smoking cessation [12,13]. We
therefore sought to determine whether CYP2A6 and nicotine
metabolism might contribute to the reported association [11] with
SNPs in the adjacent CYP2B6 locus.
However, contrary to our expectations, the data presented in
this study indicate that rs8109525 and other closely linked SNPs
are significantly associated with nicotine metabolism independent
of CYP2A6 genotype. Furthermore, we find that rs8109525 is
significantly associated with hepatic CYP2B6 expression. Impor-
tantly, both associations are independent of the well-studied
CYP2B6 alleles, *5 (rs3211371) and *6 (rs3745274/rs2279343),
which are defined by common amino acid changes associated with
altered metabolism of other substrates. Complicating these results,
CYP2B6 variants including rs8109525 and rs3745274/rs2279343
are also shown to be associated with aberrant CYP2B6 mRNA
splicing. Splicing of mRNA is a key regulatory point for gene
expression (reviewed in [14]). Rare variants that disrupt splicing or
alter the inclusion of both constitutive and alternatively-spliced
exons have been associated with disease [15–23]. Common alleles
that alter splicing provide a portion of the genetically determined
variance in clinically-relevant traits including nicotine metabolism
[24]. The importance of maintaining the balance of exon splicing
enhancer and suppressor motifs is demonstrated by the relative
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infrequency of SNPs that disrupt these motifs, especially near exon
boundaries [25,26]. Aberrant CYP2B6 mRNA splicing is common
and diverse [27,28]. Here we demonstrate associations between
genetic variation and CYP2B6 mRNA splicing involving many
aberrant forms; together with differences in allelic expression,
variation in splicing may provide a mechanism underlying
common functional differences between CYP2B6 haplotypes.
Materials and Methods
This study complies with the Code of Ethics of the World
Medical Association and obtained written informed consent from
participants. The Human Studies Committee at the Washington
University School of Medicine in Saint Louis approved the study.
The approval number for the Collaborative Genetic Study of
Nicotine Dependence (COGEND) is 00-0203. Participant recruit-
ment from COGEND [29], nicotine metabolism measures and
CYP2A6 genotyping in 189 European Americans were previously
described [6,30] (Table S1). Application of the predictive model of
CYP2A6 activity was previously described [30]. Briefly, all
analyses of measured metabolism were linear regression analyses
performed on a metabolism metric, the ratio of deuterated (D2)-
cotinine/(D2-cotinine+ D2-nicotine), determined 30 minutes fol-
lowing oral administration of D2-nicotine. The original model
parameters were derived from the regression, log (1 – metric) =
log(a) + log(bH1) + log(bH2) where a is the intercept, bH1
represents the first CYP2A6 haplotype and bH2 represents the
second CYP2A6 haplotype for each subject. For subjects of
European descent, the metric can be determined from genotype
based on six SNPs and CYP2A6 gene copy number as described in
table S2. Statistical analyses were performed using the software
package ‘R’ (R Foundation for Statistical Computing, Vienna,
Austria). All t-tests performed were two-sided.
Genotyping and Haplotype Determination
CYP2A6 and CYP2B6 nomenclature follows official recommen-
dations (http://www.cypalleles.ki.se) except that CYP2A6*1A is
defined by the A allele of rs1137115 throughout. rs1808682
genotype was previously determined using a custom designed
array as part of a larger study [29]. Genotyping of additional
CYP2B6 SNPs (Table 1) was performed using the KBioscience
Competitive Allele Specific PCR genotyping system (KASPar,
Figure 1. LD structure of the CYP2A6/CYP2B6 locus for common SNPs genotyped in the COGEND metabolism study. Numbers refer to
pairwise R2.
doi:10.1371/journal.pone.0079700.g001
CYP2B6 Expression, Splicing, and Metabolism
PLOS ONE | www.plosone.org 3 November 2013 | Volume 8 | Issue 11 | e79700
KBioscience, Hoddesdon, Herts, UK) following standard proce-
dures with custom designed primers (Table S3). KASPar assays
were set up as 8ml reactions and measured with the 7900HT Fast
Real Time PCR System (Applied Biosytems, Foster City, CA,
USA). CYP2B6 haplotypes were determined using PHASE version
2.1.1 [31,32]. Linkage disequilibrium was determined using
Haploview [33].
Allelic expression study
DNA and RNA extracted from ninety-nine de-identified normal
liver biopsy samples from patients of European descent were
supplied by the Tissue Procurement Core, Laboratory for
Translational Pathology at the Siteman Cancer Center, Washing-
ton University Medical Center. cDNA was prepared from total
RNA using the Applied Biosystem High Capacity cDNA Reverse
Transcription Kit. cDNA and genomic DNA (gDNAs) from
heterozygotes for the assayed SNPs were arrayed together in the
same 384-well plates in triplicate, and were run on an ABI-7900
real-time PCR system under standard conditions with assays for
rs3211371 (C_30634242_40, Applied Biosystems) and a custom
designed assay for rs2279343 (AHBJ12M, Applied Biosystems).
The relative expression of both alleles for each expression marker
was determined by subtracting the smaller Ct value of one allele
PCR reaction from the larger Ct value of the other allele PCR
reaction (DCt). For the statistical analysis, DCt values were
obtained as an average of two or three reactions for each sample
and data point. Allelic ratios for cDNA were normalized against
the average ratio obtained from gDNA for each genotype and
marker SNP. For the rs3211371 assay mean gDNA DCts for
rs8109525/rs8100458 heterozygotes and homozygotes were –
0.9860.06 and –0.8860.09 respectively. For the rs2279343 assay
mean gDNA DCts for rs8109525/rs8100458 heterozygotes and
homozygotes were –2.3160.08 and –2.3360.07 respectively. By
comparison, mean cDNA DCts for rs8109525/rs8100458 hetero-
zygotes and homozygotes were 0.1160.13 versus –0.3660.38 for
the rs3211371 assay and –0.2660.45 versus 1.2760.51 for the
rs2279343 assay.
Quantitative Real-time splice-form expression study
PCR products of the correct size were confirmed for all primer
pairs (primer sequences, Table S4) by agarose gel electrophoresis
(Figure S1). Reactions for pairs of assays to be compared in each
experiment were arrayed together in the same 384-well plate in
duplicate pairs, and run on an ABI-7900 real-time PCR system
under standard conditions. 10ml reactions included 2x PerfeCTa
SYBR Green FastMix ROX (Quant Biosciences Inc., Gaithers-
burg MD, USA), 0.5 mM each forward and reverse primer, and 1
ml cDNA. Dissociation curves for all primer pairs demonstrated
single peaks consistent with little contamination from primer-
dimers. Ct values were obtained as the average of two reactions for
each sample and assay. The difference in relative quantity detected
by each assay was determined by subtracting the smaller average
Ct value of one reaction from the larger average Ct value of the
other reaction.
Results
CYP2B6 polymorphisms and haplotypes associated with
the ratio of nicotine metabolized to cotinine
We initially investigated two SNPs, rs8109525, located 5
kilobases 5’ of CYP2B6, and rs8100458, in the first intron of
CYP2B6, which is in high linkage disequilibrium (R2.0.95) with
rs8109525. rs8109525 demonstrated the most significant associa-
tion with continuous abstinence at weeks 9–12 of treatment in a
previous study [11]. Although neither SNP is in high linkage
disequilibrium with any of the key CYP2A6 polymorphisms (Figure
1), both are associated with a small influence upon nicotine
metabolism in this data set (rs8109525 p= 0.041, rs8100458 p=
0.024). Both SNP associations with nicotine metabolism remain
significant and even improve after inclusion in multivariate
regression analyses with CYP2A6 haplotype variables (rs8109525
p= 0.012 or rs8100458 p= 0.0086), demonstrating that these
associations are independent of known CYP2A6 variants. Previous
studies have found that the effect of CYP2B6 genotype on nicotine
clearance is most prominent among subjects with slower metab-
olizer CYP2A6 genotypes [34]. Consistent with this hypothesis, we
find that the effect is greater among subjects with slower
metabolizing CYP2A6 genotypes (parameter estimate = 0.056,
p = 0.002 among n=34 carriers of CYP2A6*2,*4,*9,*12 and *38
alleles), than among subjects with fast metabolizing genotypes
(parameter estimate = 0.011, p= 0.087 among n=97 subjects
excluding CYP2A6*1A,*2,*4,*9,*12 and *38 carriers).
We also genotyped rs1808682, a SNP .7kb 59 of CYP2B6
which was reported to be significantly associated with continuous
abstinence at weeks 9–52 of smoking cessation treatment [11].
rs1808682 is also associated with nicotine metabolism (p = 0.040),
but this association does not remain significant (p = 0.23) in the
multivariate analysis including CYP2A6 haplotypes.
Three non-synonymous SNPs in CYP2B6 which define the
common haplotypes CYP2B6*5 and *6 (rs3211371, rs3745274,
and rs2279343, Table 1) are in strong disequilibrium with
rs8109525 and rs8100458 (D9.0.8, R2,0.15, Figure 1). We
hypothesized that one or more of these variants might be
responsible for, or confound, the significant associations observed
between the non-coding SNPs and nicotine metabolism. To refine
the association by creating more complete CYP2B6 haplotypes, we
genotyped these SNPs (rs3211371, rs3745274, and rs2279343),
along with the other common (.2% frequency) non-synonymous
Table 2. CYP2B6 haplotypes associated with D2cotinine/







intercept 0.87 0.01 ,10216
CYP2A6*1A 56 –0.05 0.01 1.261027
CYP2A6*2 12 –0.18 0.02 ,10216
CYP2A6*4 6 –0.21 0.03 3.1610214
CYP2A6*9 23 –0.06 0.01 6.961026
CYP2A6*12 8 –0.16 0.02 8.0610212
CYP2A6*38 2 –0.23 0.04 6.261027
CYP2B6*1/2
rs8109525A
105 0.02 0.01 0.015
CYP2B6*5 52 0.02 0.01 0.015
CYP2B6*6 95 0.02 0.01 0.036
athe probability that the parameter estimate is different by chance from the
reference, i.e. all CYP2A6 (n = 271) and CYP2B6 (n = 126) alleles not included in
the multivariate regression. All CYP2A6 alleles presented are loss-of-function
alleles associated with reduced metabolism (2) relative to the reference CYP2A6
alleles; all CYP2B6 alleles presented are associated with increased metabolism
(+) relative to the reference (rs8109525G) CYP2B6 alleles. rs8109525 is in high
linkage disequilibrium with rs8100458 (R2.0.95).
doi:10.1371/journal.pone.0079700.t002
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SNPs in CYP2B6, and six rarer SNPs previously shown to affect
CYP2B6 function [35] (Table 1).
Contrary to our expectation, haplotypes CYP2B*5 and *6 did
not explain the association between nicotine metabolism and
rs8109525/rs8100458. In multivariate analyses including CYP2A6
haplotypes, CYP2B6*5, CYP2B6*6, and the rs8109525 or
rs8100458 major allele reference haplotypes (CYP2B6*1A and
*2), all alleles remained independently associated with faster
metabolism (Table 2). Multivariate analyses with CYP2A6 haplotypes
and rs8109525 or rs8100458 minor allele reference haplotypes were
also significantly associated with metabolism (rs8109525 p=
0.0041, rs8100458C p= 0.0068), providing further evidence that
non-coding variants significantly influence CYP2B6 function.
Because rs8109525, rs8100458 or other closely linked SNPs
were not associated with any demonstrated or predicted effects on
gene function, we also pursued an unbiased approach to identify
further SNPs or haplotypes associated with CYP2B6 activity by
repeating the multivariate analysis including CYP2A6 haplotypes
in combination with sixteen SNPs across the CYP2B6 locus
previously genotyped in this sample [29]. Among these, the SNP
most significantly associated with nicotine metabolism was
rs3786552 (p = 0.0061) a variant in the eighth intron in linkage
disequilibrium (LD) with rs8109525 (R2= 0.59, D9=0.80). The
two SNPs are not independently statistically significantly associ-
ated with metabolism.
In summary, these data demonstrate that CYP2B6 haplotypes,
defined by non-coding variants, are associated with differences in
nicotine metabolism independent of CYP2A6 genotype. By
contrast, we do not detect differences in nicotine metabolism
associated with the common amino acid changes that define the
CYP2B6*5 and CYP2B6*6 alleles.
CYP2B6 variants associated with nicotine metabolism are
associated with gene expression
Because the association between non-coding SNPs in the
CYP2B6 locus and nicotine metabolism was independent of
known linked non-synonymous SNPs, we hypothesized that the
effect might be due to mechanisms other than altered protein
function. rs8100458 is in perfect linkage disequilibrium (R2= 1)
with rs7254579 (–2320t.c) [36], a polymorphism predicted to
disrupt a GATA transcription factor binding site [37] which tags
both of the common CYP2B6 reference haplotypes *1A and *1H/J
(Table 1). To determine whether the genetic variants associated
with nicotine metabolism were also associated with differences in
gene expression we measured allelic expression using allele-specific
assays in liver cDNAs from heterozygous individuals. An
Figure 2. The ratio of allele-specific gene expression (DCt) for cDNAs from rs3211371 (CYP2B6*5) heterozygous liver biopsy
samples. Samples, excluding rs2279343 heterozygotes, are either heterozygous (CT) at rs8100458 (C/*5, n = 5), or rs8100458 TT homozygotes (T/*5,
n = 4). DCt differs significantly by genotype (p = 0.025). Relative expression, DCt, was determined by subtracting the smaller Ct value of one allele PCR
reaction from the larger Ct value of the other allele PCR reaction normalized against the average ratio obtained from gDNAs for each genotype. The
boxplot provides a summary of the data distribution. The box represents the interquartile range, which includes 50% of values. The line across the
box indicates the median. The whisker lines extend to the highest and lowest values that are within 1.5x the interquartile range. Further outliers are
marked with circles.
doi:10.1371/journal.pone.0079700.g002
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advantage of this approach is that it avoids confounding factors
associated with total expression such as tissue sample quality, diet
or disease, and therefore allows differences between alleles to be
demonstrated in relatively small numbers of subjects heterozygous
for assayable coding SNPs.
Ninety-nine European American liver samples were genotyped
for rs8109525, rs8100458, rs3211371, rs3745274, rs2279343, and
rs3786552. rs8109525 and rs8100458 were in perfect linkage
disequilibrium (R2= 1) in these samples. Because rs3211371,
rs3745274, and rs2279343 are reported to be tightly linked to
rs8109525/rs8100458 (D9=1 [36], R2,0.15, Figure 1), for the
purpose of these analysis, CYP2B6*5 and *6 were assumed to be
rs8109525/rs8100458 major allele haplotypes; this assumption
could decrease our ability to detect real differences in allelic
expression associated with rs8109525/rs8100458. In both sets of
heterozygotes, using TaqMan assays for the SNPs rs3211371 and
rs2279343 respectively, significantly different relative allelic
expression was found between rs8109525/rs8100458 heterozy-
gotes and homozygotes (for the rs3211371 assay, 1.0960.13 vs.
0.5260.38, p = 0.025, Figure 2; for rs2279343, 2.0560.45 vs.
1.0660.51, p= 2.461026, Figure 3), consistent with lower
expression of the minor allele haplotype and similar expression
among different major allele haplotypes. Analyses of the
rs2279343 assay data also find significant differences between
rs3786552 major allele homozygotes and heterozygotes (data not
shown). By comparison, using total expression assays we were not
able to detect statistically significant differences in total CYP2B6
expression predicted by any of these variants in this small sample
(data not shown). Our results indicate differences in CYP2B6 allelic
expression that are associated with non-coding variation in the
locus; this difference in expression provides a potential mechanism
to explain why nicotine metabolism is associated with CYP2B6
haplotype independent of coding variation in CYP2A6 and
CYP2B6.
CYP2B6 variants associated with aberrant splicing
At least ten alternatively-spliced CYP2B6 transcripts have been
detected in human cDNAs, including a splice-form, SV1,
associated with the CYP2B6*6 allele [27]. Allelic differences in
expression might be due to differences in splicing efficiency and a
preponderance of aberrantly-spliced transcripts produced by
particular alleles. To determine the association between aberrant
splicing and CYP2B6 variants associated with nicotine metabolism
or smoking cessation we chose to focus on five types of aberrant
splicing previously detected in CYP2B6: 1) skipping exons 4–6
resulting in the splice-form called SV1; 2) inclusion of an
Figure 3. The ratio of allele-specific gene expression (DCt) for cDNAs from rs2279343 (CYP2B6*6) heterozygous liver biopsy
samples. Samples, excluding rs3211371 heterozygotes, are either heterozygous (CT) at rs8100458 (C/*6, n = 15) or rs8100458 TT homozygotes (T/*6,
n = 19). DCt differs significantly by genotype (p = 2.461026). Relative expression, DCt, was determined by subtracting the smaller Ct value of one
allele PCR reaction from the larger Ct value of the other allele PCR reaction normalized against the average ratio obtained from gDNAs for each
genotype. The boxplot provides a summary of the data distribution. The box represents the interquartile range, which includes 50% of values. The
line across the box indicates the median. The whisker lines extend to the highest and lowest values that are within 1.5x the interquartile range.
Further outliers are marked with circles.
doi:10.1371/journal.pone.0079700.g003
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additional exon (called 3A or 3B) between exons 3 and 4, resulting
in splice-forms SV2, SV3, SV4 or SV5; 3) skipping exon 4
resulting in splice-forms SV7 or SV8; 4) skipping exon 8 resulting
in splice-form SV9 or lMP1; and 5) inclusion of an alternative
eighth exon (8A) resulting in a splice-form called lMP8 (Figure 4)
[27,28,38]. With the exception of SV1, which lacks 160 amino
acids including several in the active site but remains in frame, all of
these alternative splicing events result in frame-shifts and
premature stop codons. PCR primers were designed to cross exon
splice junctions specific to different transcripts for quantitative
real-time PCR assays. Stepwise regression analyses were per-
formed on the different ratios of alternatively spliced transcripts
(difference in PCR cycle time (DCT)) (Figure 4) using SNPs
rs8100458, rs3786552, rs3211371 (CYP2B6*5), and rs3745274
(CYP2B6*6) as variables to determine those that optimally predict
the relative concentration of alternatively spliced transcripts in the
liver cDNAs.
Our results confirm that skipping of exons 4-6 resulting in SV1
is highly-significantly and specifically associated with the
CYP2B6*6 allele (rs3745274, Table 3, Figure 5). SV1 is relatively
common among CYP2B6*6 homozygotes—9:1 versus .110:1—
i.e. transcripts containing the exon 6-7 splice junction outnumber
those with aberrant exon 3-7 splice junction by,9:1 in CYP2B6*6
homozygotes (mean difference in PCR cycle time (DCt) = 3.2,
median = 2.9) compared to a ratio of .110:1 (mean DCt = 6.8,
median = 7.0) in non-CYP2B6*6 carriers (Figures 4 & 5). Other
aberrant-splicing events appeared to be more common than SV1
across all genotypes, and were also significantly associated with
CYP2B6 genotype (Tables 4–7, Figures 6–9). The variant
rs3211371, which defines the CYP2B6*5 allele, was not included
in any optimum model that predicts aberrant splicing. Our results
demonstrate a large potential range in expression of full-length
CYP2B6 transcript associated with different haplotypes.
Discussion
Non-coding variants in the CYP2B6 locus were recently
identified as the most significant associations with smoking
cessation in a candidate gene association study that included 785
SNPs in 24 genes [11]. The CYP2B6 enzyme has relatively little in
vitro activity toward nicotine [8], but it is relevant to smoking-
related phenotypes as the chief catalyst responsible for metabolism
of the cessation drug bupropion. Intriguingly, the associations with
cessation appeared to be independent of bupropion treatment. A
possible solution to this mystery proposed by those authors [11]
was that the SNPs were in high LD with functional variation in
CYP2A6, the primary nicotine metabolism enzyme. CYP2B6 and
CYP2A6 are located on chromosome 19 approximately 100
Figure 4. Common CYP2B6 splice-forms, and the relative locations of primers used in quantitative real-time splice-form expression
assays. Splice form nomenclature follows prior literature [27,28,38]. The locations of common non-synonymous variants are marked on the full-
length transcript. Not to scale.
doi:10.1371/journal.pone.0079700.g004
Table 3. CYP2B6 variants predicting aberrant exon 327
splicing (skipping exons 426), generating the SV1 splice-form,










rs3745274*6 0.66 4.1610223 22.260.2 4.1610223
rs3211371*5 0.03 0.06
Total adjusted R2 optimum model 0.66
aDifference in PCR cycle time (DCt) determined by subtracting the Ct value of
the PCR reaction using primers ‘6/7F’ and ‘7R’ from the Ct value of the PCR
reaction using primers ‘3/7F’ and ‘7R’ (see Figure 4, primer sequences in table
S4).
doi:10.1371/journal.pone.0079700.t003
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kilobases apart, suggesting that the non-coding variant identified
might represent a ‘synthetic association’ i.e. a proxy SNP that joins
through linkage disequilibrium multiple alleles, perhaps of both
genes, thereby combining their effects upon bupropion and/or
nicotine metabolism to result in the identified association with
smoking cessation. However, contrary to this notion, we find that
the variant is not closely linked to any functional variants in
CYP2A6, and we show that non-coding variants in CYP2B6 are
significantly associated with differences in hepatic nicotine
metabolism independent of coding variants in both CYP2A6 and
CYP2B6.
Figure 5. The ratio of aberrant exon 3-7 splicing (generating the SV1 splice-form) to correct exon 6-7 splicing. The difference in PCR
cycle times (DCt) for cDNAs for (n) liver biopsy samples divided by rs3745274 (CYP2B6*6) genotype, as dictated by the optimum model predicting DCt
(Table 3). Relative expression, DCt, was determined by subtracting the Ct value of the PCR reaction using primers ‘6/7F’ and ‘7R’ from the Ct value of
the PCR reaction using primers ‘3/7F’ and ‘7R’ (Fig. 4). The boxplot provides a summary of the data distribution. The box represents the interquartile
range, which includes 50% of values. The line across the box indicates the median. The whisker lines extend to the highest and lowest values that are
within 1.5x the interquartile range. Further outliers are marked with circles.
doi:10.1371/journal.pone.0079700.g005
Table 4. CYP2B6 variants predicting aberrant exon 3-3A/B
splicing, generating the SV2-5 splice-forms, versus all








rs3786552 0 0.5 20.560.2 5.261023
rs3745274*6 0.08 4.561023 20.860.2 8.661025
rs3211371*5 0 0.3
Total adjusted R2 optimum model 0.15
aDifference in PCR cycle time (DCt) determined by subtracting the Ct value of
the PCR reaction using primers ‘2/3F’ and ‘4R’ from the Ct value of the PCR
reaction using primers ‘2/3F’ and ‘3/3AB R’ (see Figure 4, primer sequences in
table S4).
doi:10.1371/journal.pone.0079700.t004
Table 5. CYP2B6 variants predicting aberrant exon 3-5
splicing, generating the SV7-8 splice-forms, versus all








rs3786552 0 0.9 20.760.2 1.161024
rs3745274*6 0.28 3.361028 21.460.2 8.4610212
rs3211371*5 0.03 0.04
Total adjusted R2 optimum model 0.40
aDifference in PCR cycle time (DCt) determined by subtracting the Ct value of
the PCR reaction using primers ‘2/3F’ and ‘4R’ from the Ct value of the PCR
reaction using primers ‘2/3F’ and ‘3/5R’ (see Figure 4, primer sequences in table
S4).
doi:10.1371/journal.pone.0079700.t005
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Prior investigations of genetic variation in CYP2B6 have largely
confined themselves to non-synonymous differences, focusing in
particular on the common haplotype CYP2B6*6 which differs from
the reference allele CYP2B6*1 by two amino acids (Q172.H and
K262.R, table 1). Over forty publications in the last decade have
addressed the question of CYP2B6*6 activity and have found its
effect to be substrate specific; CYP2B6*6 is associated with slower
metabolism of efavirenz [39243] and methadone [44246], but
faster clearance of cyclophosphamide [47249] and perhaps other
substrates [50,51] including nicotine and cotinine [34]. Reports
have also confirmed opposite effects of the *6 variants on
metabolism of efavirenz versus cyclophosphamide in vitro [52].
Table 6. CYP2B6 variants predicting aberrant exon 7-9
splicing, generating the SV9 and lMP1 splice-forms, versus









rs3745274*6 0.08 3.561023 20.360.1 3.561023
rs3211371*5 0 0.3
Total adjusted R2 optimum model 0.08
aDifference in PCR cycle time (DCt) determined by subtracting the Ct value of
the PCR reaction using primers ‘7/8F’ and ‘9R’ from the Ct value of the PCR
reaction using primers ‘7/9F’ and ‘9R’ (see Figure 4, primer sequences in table
S4).
doi:10.1371/journal.pone.0079700.t006
Table 7. CYP2B6 variants predicting aberrant exon 7-8A
splicing, generating the lMP8 splice-form, versus correct exon








rs3745274*6 0.34 6.5610210 20.760.1 3.0610210
rs3211371*5 0.04 0.03
Total adjusted R2 optimum model 0.34
aDifference in PCR cycle time (DCt) determined by subtracting the Ct value of
the PCR reaction using primers ‘7/8F’ and ‘9R’ from the Ct value of the PCR
reaction using primers ‘7/8A F’ and ‘9R’ (see Figure 4, primer sequences in table
S4).
doi:10.1371/journal.pone.0079700.t007
Figure 6. The ratio of aberrant exon 3-3A/B splicing (generating the SV2-5 splice-forms) to all transcripts that include exons 2, 3 &
4. The difference in PCR cycle times (DCt) for cDNAs for (n) liver biopsy samples divided by rs3745274 (CYP2B6*6) and rs3786552 genotype, as
dictated by the optimum model predicting DCt (Table 4). Relative expression, DCt, was determined by subtracting the Ct value of the PCR reaction
using primers ‘2/3F’ and ‘4R’ from the Ct value of the PCR reaction using primers ‘2/3F’ and ‘3/3AB R’ (Fig. 4). The boxplot provides a summary of the
data distribution. The box represents the interquartile range, which includes 50% of values. The line across the box indicates the median. The whisker
lines extend to the highest and lowest values that are within 1.5x the interquartile range. Further outliers are marked with circles.
doi:10.1371/journal.pone.0079700.g006
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The mechanisms by which common polymorphisms in CYP2B6
affect function remain poorly understood. The minor allele of the
non-synonymous variant rs3745274 (Q172.H) is predicted to
alter an exon splicing enhancer site [28]and Hofmann et al [27]
demonstrated that it causes aberrant splicing of CYP2B6*6
transcripts to produce the SV1 splice-form lacking three internal
exons. However, aberrant splicing cannot explain the apparent
relative higher activity of CYP2B6*6 toward cyclophosphamide or
nicotine [34]. Variation in splicing creates a special barrier to
predicting gene function from genotype because it changes both
the function and relative abundance of different transcripts.
Aberrant CYP2B6 splicing is very common and diverse and may
be caused by many individual variants that interact with each
other across the locus. The strong and specific association between
the SV1 alternative splice-form and the *6 allele was previously
reported and asserted as the key mechanism leading to altered *6
activity [27]. But our results indicate that aberrant production of
SV1 may not be the primary contributor to reduced CYP2B6*6
expression. Unlike the prior study, our findings are based on
comparison of assays amplifying PCR products of similar size
(Figure S1) rather than comparing amplification of different
products that include or skip three exons [27]. In fact, among the
five aberrant splicing events assayed here that result in at least ten
reported alternative splice-forms, all appear to be relatively
common with the exception of SV1, which is rare in non-
CYP2B6*6 carriers. Of course, quantifying transcript splicing in
cDNAs cannot indicate the degree to which any particular
alternative splice form displaces the expression of functional full-
length transcript because of differences in perdurance of different
splice-forms.
Our data also indicate differences in CYP2B6 mRNA expression
associated with genotype that cannot be straightforwardly
explained by variation in alternative splicing. This variation
appears to be associated with small differences in hepatic nicotine
metabolism. rs8109525 and rs8100458, the key CYP2B6 SNPs
associated with smoking cessation [11] and nicotine metabolism,
are also in high linkage disequilibrium (R2.0.98) with rs7254579
(-2320t.c) [36], a polymorphism predicted to disrupt a GATA
transcription factor binding site [37]. This SNP and another,
rs4802101 (called -750t.c [28]), predicted to disrupt an HNF-1a
site, define three common classes of CYP2B6 haplotypes previously
described: *1A (TT), *1H/J (CC) and *6B (TC) (Table 1).
rs7254579 and rs4803417 were each formerly investigated for
their association with total CYP2B6 expression yielding ambiguous
results [37]. Given our results together with those of Hofmann et al
[27], it is clear that the analysis of either SNP singly could be
confounded by the consequences of the *6 allele or of other genetic
variation upon splicing (i.e. exon skipping) depending on the
targets of expression assay probes. The use of TaqMan allelic
expression assays to determine the relative expression of two
haplotypes in heterozygotes can partially ameliorate this problem
by focusing experiments on particular haplotypes, as well as by
correcting for the large amount of variance in total gene
expression attributable to non-genetic factors. We were able to
assay two SNPs, rs2279343 and rs3211371, located in exons 5 and
9 respectively. Both variants therefore occur in all identified
Figure 7. The ratio of aberrant exon 3-5 splicing (generating the SV7-8 splice-forms) to all transcripts that include exons 2, 3 & 4.
The difference in PCR cycle times (DCt) for cDNAs for (n) liver biopsy samples divided by rs3745274 (CYP2B6*6) and rs3786552 genotype, as dictated
by the optimum model predicting DCt (Table 5). Relative expression, DCt, was determined by subtracting the Ct value of the PCR reaction using
primers ‘2/3F’ and ‘4R’ from the Ct value of the PCR reaction using primers ‘2/3F’ and ‘3/5R’ (Fig. 4). The boxplot provides a summary of the data
distribution. The box represents the interquartile range, which includes 50% of values. The line across the box indicates the median. The whisker lines
extend to the highest and lowest values that are within 1.5x the interquartile range.
doi:10.1371/journal.pone.0079700.g007
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alternative splice forms with the exception of SV1. Results from
both assays indicate that *1A is more highly expressed than *1H/
*1J, consistent with other published expression data [37] and
parallel to the relatively large but not statistically significant
difference reported by Hofmann et al [27]. These results indicate
that there are genetically determined differences in CYP2B6
expression that are not explained by differences in splicing.
Our results demonstrate that common functional variation in
the CYP2B6 locus does not begin and end with CYP2B6*6.
Ultimately, we must conclude that variation across the CYP2B6
locus influences expression and splicing that may lead to
differences in in vivo CYP2B6 activity which are however
impossible to predict from in vitro results alone. These differences
may account for previous contradictory reports regarding the
influence of CYP2B6 genotype upon bupropion metabolism
[53,54] or smoking cessation [55258]. Fortunately, associations
between genotype and function can be examined without first fully
elaborating the molecular mechanisms underlying the functional
differences. In a recent in vivo study of nicotine metabolism we
conducted in ,200 subjects we were able to define activities of
different common CYP2A6 haplotypes with high confidence based
on few assumptions about the functional effects of the variants
[30]. In multiple instances those in vivo results forced a reevaluation
of assumptions about specific alleles that had been made based on
in vitro experiments. Those findings also indicated previously
unrecognized differences between alleles that we subsequently
determined to be associated with mRNA splicing efficiency [24].
In the case of CYP2B6, much of the common variation would
appear to affect gene transcription or splicing, and these are not
likely to be substrate specific. These discrepancies could be
resolved using a similar in vivo metabolism experiment with an
appropriate CYP2B6 substrate, a sufficient number of subjects,
and most importantly, thorough determination of CYP2B6
haplotypes. Such comprehensive results may then allow us to
retrospectively understand how the diversity of variation in
expression, splicing, and enzyme activity collaborate to determine
the relative impacts of different common CYP2B6 alleles on
metabolism and smoking cessation.
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Figure 8. The ratio of aberrant exon 7-9 splicing (generating the SV9/lMP1 splice-forms) to correct exon 7-8 splicing. The difference
in PCR cycle times (DCt) for cDNAs for (n) liver biopsy samples divided by rs3745274 (CYP2B6*6) genotype, as dictated by the optimum model
predicting DCt (Table 6). Relative expression, DCt, was determined by subtracting the Ct value of the PCR reaction using primers ‘7/8F’ and ‘9R’ from
the Ct value of the PCR reaction using primers ‘7/9F’ and ‘9R’ (Fig. 4). The boxplot provides a summary of the data distribution. The box represents the
interquartile range, which includes 50% of values. The line across the box indicates the median. The whisker lines extend to the highest and lowest
values that are within 1.5x the interquartile range. Further outliers are marked with circles.
doi:10.1371/journal.pone.0079700.g008
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